Third Annual Pediatric Cancer Symposium

Milwaukee, WI US
May 19, 2016

The Third Annual Pediatric Cancer Symposium is designed to provide the latest information on Emerging Cancer Therapies: Targeting the Tumor Microenvironment and will benefit health care providers and researchers who work with childhood cancers and researchers.

It will allow pediatric cancer providers and researchers an opportunity to network, collaborate and advance treatment and research in discovering new cancer therapies. 

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for up to 5.0 hours of participation for continuing education for allied health professionals.

Target Audience

Physicians, Allied Health Care Professionals

Learning Objectives

Describe the threshold effect of localized IL-12 overexpression in driving anti-cancer immunotherapy.

Delineate the mechanisms of localized IL-12 effects in antigen-independent immunotherapy.

Outline a novel clinical gene therapy trial that has been approved for this approach in treating AML and is actively recruiting patients.

Define the different mechanisms that contribute to tumor heterogeneity

Understand how the microenvironment interacts with tumor cells to contribute to cell plasticity

Understand how cell plasticity functions as a major mediator of Ewing sarcoma metastasis

Discuss the potential therapeutic implications of this for cancer therapy

Understand basic principles of B cell selection and cellular origins of childhood ALL

Compare the paradigm of targeted therapy in cancer (e.g. tyrosine kinase inhibitors) with targeted hyperactivation of signaling (tolerance checkpoints).

Discuss how pharmacological hyperactivation of oncogenic signaling triggers deletional checkpoints for elimination of autoreactive B cells

Review the current clinical and biological biomarkers that are utilized to risk classify neuroblastoma patients and stratify treatment.

Describe the germline genomic variants that contribute to the phenotype of neuroblastoma tumors 3. To discuss the observed racial and ethnic disparities in survival in neuroblastoma and the factors that contribute to these disparities.

Additional information

CME Coordinator Contact Information

Name: 
Nancy Vanselow
Phone Number: 
+1 (414) 266-6556
Course summary
Available credit: 
  • 5.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 5.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
04/25/2016
Course expires: 
08/31/2016
Event starts: 
05/19/2016 - 8:00am
Event ends: 
05/19/2016 - 3:30pm
Cost:
$0.00
Harley Davidson Museum
400 W. Canal St.
Milwaukee, WI 53201
United States

Iron Horse Hotel

www.theironhorsehotel.com

Address: 500 W Florida St, Milwaukee, WI 53204

Program Director: Michael Kelly, MD, MPH

Program Speakers: 
Thomas Gajewski, MD, PhD
Raghu Kalluri, MD, PhD
Elizabeth Lawlor, MD, PhD
Jeffrey Medin, PhD
Markus Muschen, MD, PhD

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following person(s)

Susan Cohn, MD

Presenter

CELGENE CORP
DEPOMED INC COM
DR REDDY LABS LTD ADR
EDWARDS LIFESCIENCES CORP COM
HANSEN MED INC COM NEW
HANSEN MED INC COM NEW
MEDNAX INC COM
NOVARTIS AG SPONSORED ADR
HENRY SCHEIN INC
TEVA PHARMACEUTICAL INDUSTRIES LTD ADR ISIN#US8816242098
UNITED THERAPEUTICS CORP DEL COM
UNITEDHEALTH GROUP INC COM
UNIVERSAL HEALTH SVCS INC CL B
VARIAN MED SYS INC COM
VERMILLION INC COM NEW
ASTRAZENECA PLC SPONSORED ADR
MERCK & CO INC NEW COM
PFIZER INC COM

EDWARDS LIFESCIENCES CORP COM
FRESENIUS MED CARE AKTIENGESELLSCHAFT SPONSORED ADR REPSTG SHS ISIN#US3580291066
RESMED INC COM
UNITED THERAPEUTICS CORP DEL COM
UNIVERSAL HEALTH SVCS INC CL B
VARIAN MED SYS INC COM
ASTRAZENECA PLC SPONSORED ADR
MERCK & CO INC NEW COM
PFIZER INC COM

Stock Ownership:

Susan Cohn and husband, James Cohn

Jeffrey Medin, PhD

Presenter

AVROBIO LTD

PLEXCERA THERAPEUTICS

Ownership instrest and consulting

Speaker

Available Credit

  • 5.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 5.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
04/25/2016
Course expires: 
08/31/2016

Price

Cost:
$0.00
Please login or register to take this course.